WALTHAM, Mass., Dec. 19, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two platform technologies for treating diseases and disorders of the eye, today announced that it has been granted U.S. Patent No. 9,820,935, by the U.S. Patent and Trademark Office (USPTO). The patent, titled “Delivery of corticosteroids through iontophoresis,” covers the iontophoretic delivery of a dexamethasone phosphate formulation to a subject’s eye for the treatment of various conditions, including post-operative inflammation and uveitis. EyeGate’s product candidate, EGP-437, is a proprietary formulation of iontophoretically delivered dexamethasone phosphate currently in a Phase 3 study in uveitis and a Phase 2b study for the treatment of pain and inflammation following cataract surgery. The Company has licensed EGP-437 in both indications to a subsidiary of Valeant Pharmaceuticals.
“As we continue advancing the clinical development of our products, ensuring that we have broad patent protection for our proprietary technologies is of the utmost importance and this new patent is a significant step forward in that regard,” said Stephen From, President and Chief Executive Officer of EyeGate. “Our trials for EGP-437 are proceeding well, as we are continuing to enroll patients in both the Phase 3 uveitis study and await top-line data for the Phase 2b cataract surgery trial. We believe that our global licensing agreements with Valeant demonstrate the potential value of EGP-437 in both indications and look forward to completing the trials and moving toward anticipated NDA submissions.”
EGP-437 incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, which is delivered into the ocular tissues though EyeGate’s proprietary innovative drug delivery system, the EyeGate® II Delivery System. Iontophoresis is capable of delivering substantially higher ocular drug concentrations leading to potentially greater bioavailability and therapeutic effect, therefore reducing the frequency of dosing. The EyeGate® II Delivery System has the potential to offer a non-invasive method of drug delivery as an alternative to the current delivery modalities used for treating ocular diseases, such as eye drops and ocular injections.
EyeGate is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products using its two proprietary platform technologies for treating diseases and disorders of the eye.
EyeGate’s most advanced platform is based on a cross-linked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (“HA”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries.
EGP-437, EyeGate’s other product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system, the EyeGate II Delivery System. www.EyeGatePharma.com.
EyeGate Social Media
EyeGate uses its website (www.EyeGatePharma.com), Facebook page, corporate Twitter account, and LinkedIn page as channels of distribution of information about EyeGate and its product candidates. Such information may be deemed material information, and EyeGate may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor EyeGate’s website and its social media accounts in addition to following its press releases, SEC filings, public conference calls, and webcasts. The social media channels that EyeGate intends to use as a means of disclosing the information described above may be updated from time to time as listed on EyeGate’s investor relations website.
Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements include statements relating to, among other things, the commercialization efforts and other regulatory or marketing approval efforts pertaining to EyeGate’s products, including EyeGate’s EGP-437 combination product and those of Jade Therapeutics, Inc., a wholly owned subsidiary of EyeGate, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, certain risk factors described under the heading “Risk Factors” contained in our Annual Report on Form 10-K filed with the SEC on February 23, 2017 or described in EyeGate’s other public filings. EyeGate’s results may also be affected by factors of which EyeGate is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. EyeGate expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.